CBD Cannabis Extract: Pharmacokinetic Studies

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

December 1, 2021

Study Completion Date

December 1, 2021

Conditions
Epilepsy
Interventions
DRUG

cannabidiol extract

"The test article CBD Cannabis Extract Oral Solution will be manufactured by the University of Mississippi National Center for Natural Products Research (NCNPR) at the Coy Waller Laboratory under FDA Current Good Manufacturing Practices. The drug product, derived from hemp and containing less than 0.3% of Δ9-tetrahydrocannabinol, is no longer a Drug Enforcement Agency (DEA) controlled substance. DEA registrations are not required for the manufacturing, handling or dispensing of these clinical test materials"

Trial Locations (1)

38677

University of Mississippi, University

All Listed Sponsors
lead

University of Mississippi, Oxford

OTHER

NCT04280289 - CBD Cannabis Extract: Pharmacokinetic Studies | Biotech Hunter | Biotech Hunter